Dart Neuroscience Email Format
BiotechnologyCalifornia, United States201-500 Employees
As a mid-sized biotechnology research firm, it operates within the neuroscience and memory-therapy landscape. A notable development in late 2024 was the sale of assets to Mirumpharma, with Mirum acquiring global rights to the compound MRM-3379 (previously ENT-3379) from Enthorin Therapeutics and Dart NeuroScience. The company's activities focus on discovering and validating gene targets involved in memory formation and translating those targets into therapeutic candidates.